- Home
- AEYE vs KLRS Comparison
AEYE vs KLRS Comparison
Compare AEYE & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEYE
- KLRS
- Stock Information
- Founded
- AEYE 2005
- KLRS 2019
- Country
- AEYE United States
- KLRS United States
- Employees
- AEYE N/A
- KLRS N/A
- Industry
- AEYE Computer Software: Prepackaged Software
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AEYE Technology
- KLRS Health Care
- Exchange
- AEYE Nasdaq
- KLRS Nasdaq
- Market Cap
- AEYE 138.0M
- KLRS 129.0M
- IPO Year
- AEYE N/A
- KLRS N/A
- Fundamental
- Price
- AEYE $12.22
- KLRS $2.90
- Analyst Decision
- AEYE Strong Buy
- KLRS Buy
- Analyst Count
- AEYE 5
- KLRS 1
- Target Price
- AEYE $26.40
- KLRS N/A
- AVG Volume (30 Days)
- AEYE 113.3K
- KLRS 52.4K
- Earning Date
- AEYE 07-24-2025
- KLRS 05-14-2025
- Dividend Yield
- AEYE N/A
- KLRS N/A
- EPS Growth
- AEYE N/A
- KLRS N/A
- EPS
- AEYE N/A
- KLRS N/A
- Revenue
- AEYE $36,851,000.00
- KLRS N/A
- Revenue This Year
- AEYE $20.16
- KLRS N/A
- Revenue Next Year
- AEYE $18.74
- KLRS N/A
- P/E Ratio
- AEYE N/A
- KLRS N/A
- Revenue Growth
- AEYE 16.52
- KLRS N/A
- 52 Week Low
- AEYE $8.91
- KLRS $2.65
- 52 Week High
- AEYE $34.85
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- AEYE 48.67
- KLRS N/A
- Support Level
- AEYE $12.04
- KLRS N/A
- Resistance Level
- AEYE $13.01
- KLRS N/A
- Average True Range (ATR)
- AEYE 0.77
- KLRS 0.00
- MACD
- AEYE -0.09
- KLRS 0.00
- Stochastic Oscillator
- AEYE 7.53
- KLRS 0.00
About AEYE AudioEye Inc.
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.